Shelhigh Enters Consent Order with FDA (U. S. Food and Drug Administration)
Under a court order signed June 22, 2007, Shelhigh, Inc., of Union, N.J., agreed to stop distributing its implantable medical devices, used in heart surgery and other procedures, until the company brings its production processes in line with FDA standards.

King Pharmaceuticals And Palatin Technologies Announce End-of-Phase 2 Meeting With FDA For Bremelanotide (Medical News Today)
Palatin Technologies, Inc. (Amex: PTN) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) has scheduled an End-of-Phase 2 meeting to discuss clinical study results with bremelanotide for the treatment of erectile dysfunction (ED). [click link for full article]